- Home
- YQ vs OTLK Comparison
YQ vs OTLK Comparison
Compare YQ & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | OTLK |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 38.7M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | YQ | OTLK |
|---|---|---|
| Price | $3.67 | $0.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 7.2K | ★ 10.6M |
| Earning Date | 12-09-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,563,434.00 | $1,413,535.00 |
| Revenue This Year | N/A | $1,578.49 |
| Revenue Next Year | N/A | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.42 |
| 52 Week High | $6.45 | $3.39 |
Technical Indicators
Market Signals| Indicator | YQ | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 23.37 |
| Support Level | $3.36 | $0.42 |
| Resistance Level | $3.65 | $0.54 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 100.00 | 8.68 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.